Spots Global Cancer Trial Database for Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

Official Title: Phase I Evaluation of Interferon-alpha-1b in Solid Tumors, Lymphoma or Myeloma

Study ID: NCT00276536

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

recombinant interferon alpha-1b

IFN

Study Description

Brief Summary: RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV solid tumors, lymphoma, or myeloma.

Detailed Description: OBJECTIVES: * Confirm tolerance and safety of interferon alfa-1b (IFN-α1b) in patients with stage IV solid tumors, lymphoma, or myeloma. * Determine the maximum tolerated dose (MTD) of IFN-α1b given daily by subcutaneous injection in these patients. OUTLINE: This is a dose-escalation study. Patients receive interferon alfa-1b subcutaneously once daily for at least 1 month. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of interferon alfa-1b until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.